Jill Drake

Starting dose is a risk factor for allopurinol hypersensitivity syndrome: A proposed safe starting dose of allopurinol

Lisa K. Stamp, William J. Taylor, Peter B. Jones et al. · Arthritis & Rheumatism · 2012 · 287 citations

Medicine, Pharmacology, Pharmacotherapy +10

Treatment persistence with once-monthly ibandronate and patient support vs. once-weekly alendronate: results from the PERSIST study*

Alun Cooper, Jill Drake, E. Brankin · International Journal of Clinical Practice · 2006 · 156 citations · Full text

Pharmacy, Pharmacotherapy, Bone Metabolism +15

A randomised controlled trial of the efficacy and safety of allopurinol dose escalation to achieve target serum urate in people with gout

Lisa K. Stamp, Peter T. Chapman, Murray L. Barclay et al. · Annals of the Rheumatic Diseases · 2017 · 148 citations

Pharmacy, Pharmacology, Pharmacotherapy +17

Effects of Allopurinol Dose Escalation on Bone Erosion and Urate Volume in Gout: A Dual‐Energy Computed Tomography Imaging Study Within a Randomized, Controlled Trial

Nicola Dalbeth, Karen Billington, Anthony Doyle et al. · Arthritis & Rheumatology · 2019 · 103 citations

Medicine, Radiology, Diagnostic Radiology +13

ABCG2 loss-of-function polymorphism predicts poor response to allopurinol in patients with gout

R.L. Roberts, M C Wallace, Amanda Phipps‐Green et al. · The Pharmacogenomics Journal · 2016 · 94 citations

Medicine, Genetics, Molecular Genetics +7